Intelligence / Healthtech / New Clinical Trials / Azafaros B.V.
Clinicaltrial registered21 Oct 2026
Azafaros B.V.
21 Oct 2026: Trial registered · Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 21 Oct 2026
- Title
- Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
- Conditions
- Niemann-Pick Disease Type C, GM2 Gangliosidosis, GM1 Gangliosidosis, Gaucher Disease Type 3
- Phase
- Phase 2, Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07885917
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Azafaros B.V.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.